STREAM (Standardised Treatment Regimens of Anti-tuberculosis drugs for Multidrug-Resistant Tuberculosis) Stage 1 demonstrated non-inferior efficacy of a short regimen for rifampicin-resistant TB (RR-TB) compared to a long regimen as recommended by the World Health Organization. This study analyzed factors associated with a definite or probable failure or relapse (FoR) event in participants receiving the short regimen. The factors associated with FoR outcomes identified in this study should be considered when determining the optimal shortened treatment regimen.
Published: August 1, 2022
Sign up to receive our monthly Research Roundup email, which offers a selection of new public health research from major journals.
Recent Abstracts
Effects of Heat on Early Childhood Development
Blood Lead Surveillance of Children and Pregnant Women in Tamil Nadu, India
Sportswashing through Media: Coca-Cola’s Olympic Play – A Research Report
What’s in Our Food?
Mais Dados Mais Saúde
More Data, Better Health – Primary Health Care
Mais Dados Mais Saúde: Experiência De Discriminação Cotidiana Pela População Brasileira
More Data, Better Health – Experience of everyday Discrimination by the Brazilian population
Monitoramento de Estratégias pelo Fim da Violência contra Crianças e Adolescentes
Harm Reduction: The Neglected Pillar of US Drug Policy